The altered molecular pathways and tumor-infiltrating immune cells might associate with the mechanism of PRAS40 being a suppressor in HNSCC cells, which would provide a potential prognosis predictor and therapeutic target in HNSCC patients. This evidence concerns the gene AKT1S1 and neoplasm.